Literature DB >> 20447507

Interdisciplinary management of epidermolysis bullosa in the public setting: the Netherlands as a model of care.

José C Duipmans1, Marcel F Jonkman.   

Abstract

An interdisciplinary team approach, in which the treatment can be individualized to each patient and his or her family and tailored to the severity of the disease, is most beneficial to the patient with epidermolysis bullosa (EB). In the Netherlands, the Center for Blistering Diseases in Groningen provides a large interdisciplinary EB team that performs at a high level to provide the best EB-patient care for both children and adults. The possibility of rapid diagnosis, the efficient carrousel-like clinics, and the continuity in care are typical elements of the Dutch method of delivering interdisciplinary EB care. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20447507     DOI: 10.1016/j.det.2010.02.005

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  3 in total

1.  Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?

Authors:  R Baardman; V K Yenamandra; J C Duipmans; A M G Pasmooij; M F Jonkman; P C van den Akker; M C Bolling
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-11-16       Impact factor: 6.166

Review 2.  Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.

Authors:  May El Hachem; Giovanna Zambruno; Eva Bourdon-Lanoy; Annalisa Ciasulli; Christiane Buisson; Smail Hadj-Rabia; Andrea Diociaiuti; Carolina F Gouveia; Angela Hernández-Martín; Raul de Lucas Laguna; Mateja Dolenc-Voljč; Gianluca Tadini; Guglielmo Salvatori; Cristiana De Ranieri; Stephanie Leclerc-Mercier; Christine Bodemer
Journal:  Orphanet J Rare Dis       Date:  2014-05-20       Impact factor: 4.123

3.  Living with epidermolysis bullosa: Daily challenges and health-care needs.

Authors:  Sandra Kearney; Ann Donohoe; Eilish McAuliffe
Journal:  Health Expect       Date:  2019-12-23       Impact factor: 3.377

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.